Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Addition of rh-GMCSF to the antibiotics significantly improved the response rate (96% versus 82%, P = 0.03), but not the survival rate (93% versus 93%), in the evaluable patients. This difference in response rate was not significant when considering all patients in an intent-to-treat analysis. The number of patients who recovered from severe neutropenia ( < 100 cells/microliter) during the period of observation in the study was significantly greater among patients receiving the colony-stimulating factor, although the median duration of neutropenia was not affected. Superinfections and subsequent infections were not significantly different among the two treatment regimens. Side effects were more common among patients treated with the colony-stimulating factor. CONCLUSIONS: Our data do not support the routine administration of rh-GMCSF with antibiotics for patients with fever and neutropenia. Further studies should be conducted to identify those patients most likely to benefit from rh-GMCSF therapy, such as patients with persistent profound neutropenia and refractory infections.
|
Authors | E J Anaissie, S Vartivarian, G P Bodey, C Legrand, H Kantarjian, D Abi-Said, C Karl, S Vadhan-Raj |
Journal | The American journal of medicine
(Am J Med)
Vol. 100
Issue 1
Pg. 17-23
(Jan 1996)
ISSN: 0002-9343 [Print] United States |
PMID | 8579082
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Clavulanic Acids
- Drug Combinations
- Gentamicins
- Penicillins
- beta-Lactamase Inhibitors
- Clavulanic Acid
- Netilmicin
- Granulocyte-Macrophage Colony-Stimulating Factor
- Ticarcillin
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anti-Bacterial Agents
(administration & dosage, therapeutic use)
- Clavulanic Acid
- Clavulanic Acids
(administration & dosage, therapeutic use)
- Drug Administration Schedule
- Drug Combinations
- Escherichia coli
- Fever
(drug therapy)
- Gentamicins
(administration & dosage, therapeutic use)
- Granulocyte-Macrophage Colony-Stimulating Factor
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Middle Aged
- Neoplasms
(complications)
- Netilmicin
(administration & dosage, therapeutic use)
- Neutropenia
(drug therapy)
- Penicillins
(administration & dosage, therapeutic use)
- Prospective Studies
- Remission Induction
- Superinfection
(etiology)
- Survival Rate
- Ticarcillin
(administration & dosage, therapeutic use)
- beta-Lactamase Inhibitors
|